Kunena :: Тема: Posted by Christenson Olive on 29.11.2016 17:37:35: tarceva et vomissements (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Christenson Olive on 29.11.2016 17:37:35: tarceva et vomissements

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Christenson Olive on 29.11.2016 17:37:35: tarceva et vomissements

Страница:
1
2

ТЕМА: Posted by Christenson Olive on 29.11.2016 17:37:35: tarceva et vomissements

Posted by Christenson Olive on 29.11.2016 17:37:35: tarceva et vomissements 7 года 5 мес. назад #923

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
While there is some growing recognition of situations in which testing prospectively for an EGFR mutation may be especially helpful, particularly if you’re considering using an EGFR inhibitor as first line therapy, most oncologists would only be inclined to order the test if it has implications for how you’d manage the patient. As a general rule in medicine, it only makes sense to order tests that can change how you would intervene. If tarceva is approved as second and third line therapy for advanced NSCLC (as it is) and a patient is already on or past first line therapy, it doesn’t make much sense to me to send the test, because giving tarceva is an appropriate course of action either way. Having an EGFR mutation is associated with a very high probability of a good response and prolonged survival, but there’s still an overall anticipated survival benefit for patients who don’t necessarily have an EGFR mutation.
amorc-spb.ru/forum/dobro-pozhalovat/1886...-how-much-is-tarceva
Effect of GDC-0449, a hedgehog (Hh) pathway inhibitor, on tumor activity and on erlotinib and cisplatin in a xenograft model of non-small cell lung cancer (NSCLC) with activated Hh pathway.
To test whether YW327.6S2 could enhance the therapeutic index of standard care for NSCLC, we performed combination treatment of YW327.6S2 with epidermal growth factor receptor (EGFR) small-molecule inhibitor (SMI) erlotinib and chemotherapy.
Fourteen of the 18 (78%) patients had PD as the best response to erlotinib monotherapy, an additional 3 (16%) patients had brief periods of SD as best response, and only 1 (6%) patient had a radiographic partial response (PR; Tables 2 and 3 ).
Dziadziuszko et al. [ 32 ] demonstrated a significant correlation between MET gene copy number determined by SISH and protein expression evaluated by IHC. In the METLung clinical trial [ 18 ] of Spiegel et al. IHC was assessed using antibody clone SP44 for the determination of MET-expression. Patients with 2+ or 3+ MET expression of their tumours were included. They were stratified for the level of MET expression. There was no improvement in PFS or OS in the Intention-To-Treat (ITT) population. Expression of c-MET was associated with worse outcome. Apparently, the addition of onartuzumab to erlotinib in MET-positive patients abrogates the negative prognostic impact. But, without a diagnostic hypothesis, the results obtained in the (ITT) population lead to interrupt the development of onartuzumab. One reason for the weak responsiveness might be that not only the expression level of c-met is relevant, but also the status of receptor signaling.
new.school125.spb.ru/index.php?option=co...2&id=7817&Itemid=256
A seventh aspect of the present invention provides a pharmaceutical composition comprising erlotinib saccharinate or erlotinib maleate or hydrates thereof, and a pharmaceutically acceptable carrier.
Erlotinib con Natalizumab
forum.aide.ru/viewtopic.php?p=14501#14501
Thanks Dr. West, Jim, and Certain Spring for your responses. We appreciate the information! Sorafenib wasn’t one I was aware of so I’ll have to look into that. Another point to bring up is the possibility of re-starting Tarceva after the chemo treatment (assuming the onc thinks it wise to discontinue Tarceca during the chemo rounds). I’ve seen a few postings regarding this but wondered if any of you have specific experience in this working?
Processes for the preparation of erlotinib hydrochloride
Liver function test abnormalities (including elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin) have been observed following the administration of TARCEVA plus gemcitabine in patients with pancreatic cancer. Table 3 displays the most severe NCI-CTC grade of liver function abnormalities that developed. TARCEVA dosing should be interrupted or discontinued if changes in liver function are severe [see Dosage and Administration (2.3 )].
Side Effects & Interactions of Tarceva
Check all prescription and nonprescription medicine labels carefully since many medications contain pain relievers/fever reducers (aspirin, NSAIDs such as ibuprofen or naproxen) which may increase your risk for stomach bleeding while you are taking erlotinib. However, if your doctor has directed you to take low-dose aspirin to prevent heart attack or stroke (usually at dosages of 81-325 milligrams a day), you should keep taking the aspirin unless your doctor instructs you otherwise. Ask your doctor or pharmacist for more details.
ogff.ru/component/kunena/2-dobro-pozhalo...secundarios?Itemid=0
Tarceva blood brain barrier
Can smoking affect my treatment with Erlotinib
www.autogrodno.by/kunena/30/22028-posted...b-and-erlotinib.html
je voudrais savoir si le tarceva peut etre administre en meme temps que le gemzzar pour un cancer du panceras merci
Although HPBCD proved indispensible for the detection of erlotinib and OSI-420 in the dialysate, its presence provided a challenge as we performed the recovery experiments. Because HPBCD forms inclusion complexes with erlotinib in the perfusate limiting drug movement to brain ECF, we could not use retrodialysis or no-net-flux to estimate in vivo recovery values. Instead we chose to use the zero flow rate method to estimate recovery, realizing that as with all methods to calculate recovery, this approach has limitations. For example, the ZFR method should be applied when the target tissue (e.g. brain ECF) is at a steady-state. Our initial microdialysis experiments (n=4) conducted under constant flow rate of 0.5 μL/min showed that brain ECF concentrations dropped by only
boomboxclub.ru/forum.html?func=view&catid=16&id=796#796
By The ASCO Post December 1, 2014 Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy
Diarrhea has occurred in patients on TARCEVA and moderate or severe diarrhea should be treated with loperamide. In some cases, dose reduction may be necessary. In the event of severe or persistent diarrhea, nausea, anorexia, or vomiting associated with dehydration, TARCEVA therapy should be interrupted and appropriate measures should be taken to treat the dehydration (see Dosage and Administration).
19 . The process according to claim 18. wherein said salt of erlotinib is erlotinib hydrochloride or erlotinib methanesulfonate.
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States
"These early data suggest presurgical treatment with bevacizumab and erlotinib is safe and efficacious in patients with previously unresected, untreated metastatic RCC, with shrinkage of both the metastatic disease and primary tumors," said Eric Jonasch, MD, assistant professor of genitourinary medical oncology. "Our findings indicate that this treatment approach might be applicable to a wide range of patients with renal cell carcinoma, and that we might be able to use systemic treatment before surgery to treat many more people with metastatic disease successfully."
alfasm.ru/forum/18-trebuetsya/6337-poste...-off-label.html#6337
Between July 2006 and June 2009, 834 patients were enrolled onto 73 centers in France and received cisplatin-gemcitabine induction chemotherapy. A total of 464 patients were subsequently randomly assigned to observation (n = 155), gemcitabine (n = 154), or erlotinib (n = 155) maintenance therapy. The main reasons for nonrandomization were disease progression (22.9%), toxicity (7.1%), and death (6.8%; Fig 1 ). Baseline characteristics were well balanced among the treatment arms (Table 1 ). At data cutoff for the primary end point (August 30, 2010), 454 (97.8%) of 464 randomly assigned patients' files had been reviewed and 381 patients experienced disease progression or death ( Fig 1 ). The median follow-up period for all patients was 25.6 months.
HL Kindler. KA Bylow. HS Hochster. etal: A randomized phase II study of bevacizumab (

and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis J Clin Oncol 24: 18s. 2006 suppl abstr 4060
First Health Part D Value Plus (PDP) typically lists Tarceva in Tier 5 of their formulary. Tier 5 drugs are usually non-preferred brand-name drugs. Tier 5 drugs cost more than Tier 1, 2, 3 and 4 drugs.
13. Erlotinib and gefitinib work in a different way to chemotherapy. They are given in tablet form and are known as "targeted agents" because they block certain processes in the cancer cells.